Immunotherapy with IFNα2a/b is important for the clinical treatment of chronic hepatitis B. IFNα exhibits direct antiviral effect as well as immunomodulatory activities, which can induce sustained antiviral responses in part of the treated chronic hepatitis B patients. The gene discussed is IFNA1; the disease is chronic hepatitis B virus infection.